Given that smoking is widely known as a leading cause of increased morbidity and mortality caused by neoplastic, vascular, and respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, 7 the US Food and Drug Administration has now extended its tobacco regulatory power to include ECs. However, the research on EC use to guide these regulatory policies is currently limited but growing rapidly. We review here the available body of evidence on the safety of ECs as it relates to respiratory health and their efficacy as smoking cessation tools.
EPIDEMIOLOGIC DATA ON THE PREVALENCE OF EC USE
Since their emergence to the US market in 2007, ECs are being used, both experimentally and regularly, in increasing rates by both youths and adults, although estimates of use vary among surveys. [8] [9] [10] Representative cross-sectional surveys of US adults between 2010 and 2013 noted an increase in the proportion of subjects who reported having ever tried ECs from 1.8% to 13%. Additionally, current use of ECs, defined as use on ''some days'' or every day, increased from 0.3% to 6.8%. Current use among young adults aged 18 to 24 years surpassed that of older age groups. Caucasians and those with lower levels of education were also more likely to use ECs. Although current CC smokers were most likely to concurrently use ECs, one third of EC users identified themselves as never having used CCs or as former users of CCs. 9 The more recent 2014-2015 US Census Bureau Current Population Survey-Tobacco Use Supplement surveying more than 160,000 adults reported that 2.4% of the general US population were current EC users, whereas 8.5% of the population reported having tried ECs at least once. In addition to age, race, and education level, this survey also found male sex to be a significant predictor of current use. 8 Regardless of the survey examined, it is clear that EC use is on the rise, and the consistent report of highest use among young adults begs the question of whether this trend is seen among adolescents. Jamal et al 11 provide evidence for this through analysis of data from the 2011-2016 National Youth Tobacco Surveys, cross-sectional questionnaires administered to US middle and high school students. In 2015, 16 .0% of all high school students and 5.3% of all middle school students reported using ECs on more than 1 day in the 30 days before the survey, the definition of ''current use'' for this analysis. Increasing EC use was observed between 2011 and 2015 for both high school students (1.5% to 16.0%) and middle school students (0.6% to 5.3%). Moreover, ECs have replaced CCs since 2014 as the most commonly used tobacco product in middle school and high school youth.
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Several studies have alluded to reasons for this growth in use. In a global survey of more than 19,000 participants, former and current CC smokers reported using ECs as a means to reduce smoking-related adverse health effects and to reduce second-hand smoke exposure for family members. 1 Although smoking cessation and overall health improvement are cited as common reasons for use in middle-aged to older adults, flavorings, 12 enjoyment, 13 peer use, and curiosity 14 are more frequently cited by youth and young adults. In fact, three fourths of flavored-product users in a survey of young adults and youths in Texas claimed they would discontinue EC use if their preferred flavor was no longer available. 15 Adding to the presumed relative harmlessness of ECs and purported benefits for smoking cessation, increasing exposure to robust advertising campaigns, including discounted price promotions, have also been associated with increased use of ECs. [16] [17] [18] [19] In youth and young adults there is growing concern that the inception of EC use provides a gateway for use of additional tobacco products, although some find this theory to be unwarranted. 20 In the 2016 National Youth Tobacco Survey, 9.6% of high school students and 3.1% of middle school students reported current use of 2 or more tobacco products, 11 but whether EC use came first and/or perpetuated use of additional tobacco products is unclear. A recent meta-analysis pooled data from 9 studies examining the effect of EC use on subsequent cigarette smoking in 17,389 participants aged 14 to 30 years. 21 The pooled odds ratio for subsequent CC use after ever having used ECs was 3.62 (95% CI, 2.42-5.41), whereas the pooled odds ratio for CC use in the past 30 days in those with EC use in the past 30 days was 4.28 (95% CI, 2.52-7.27), 21 indicating a greater likelihood of smoking CCs among adolescent and young adult EC users. In addition, although the EC device is designed to be used with nicotine-containing or nicotine-free liquids, they have been adapted by young adults for use with other substances, including cannabis. 14 Thus although the data in support of the gateway theory is overall still limited, the increasing prevalence of EC use among youth and adults either alone or in combination with other products is concerning enough that understanding the beneficial and/or harmful effects of ECs is of paramount importance. A key first step to achieving this goal is through in-depth knowledge of the components of ENDSs.
ECs AND THEIR CONSTITUENTS
The specific design of ENDSs varies with each subsequent generation but continues to consist of 3 primary components: a power source (typically a rechargeable lithium battery), the heating element (an atomizer coil), and a reservoir containing the e-liquid (EL; Fig 1) . Newer-generation models allow for customization of power, resistance, and/or temperature-based on user preferences. The EL itself also consists of 3 primary components: the solvent (either vegetable glycerin, propylene glycol, or both), various flavorings, and nicotine in various doses. Heat from the atomizer coil after activation of the power source aerosolizes the EL, which is then inhaled (or ''vaped'') from the attached mouthpiece.
Although EL solvents and flavors are generally regarded as safe for oral consumption, the effects of their aerosolization and subsequent inhalation are not clearly understood and might prove damaging to airway mucosa and function. 22 Moreover, manufacturing labels are not always comprehensive in regard to EL constituents 23 and therefore might not alert the consumer to the potential for harmful effects. Depending on the combination of solvents and flavors used, a large variation in chemicals can be detected in the resultant aerosol (Fig 1) . 24, 25 These chemicals include carbonyl compounds, such as formaldehyde, acetaldehyde, acetone, and acrolein; volatile organic compounds, such as benzene and toluene; tobacco-specific nitrosamines; particulate matter; and metals, such as nickel, copper, zinc, tin, and lead. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Even when controlling for EL solvent, flavor, and nicotine content, variabilities in the chemical composition of aerosols have been detected within brands, 27 as well as within samples of the same product 33 and with the voltage of power used for generation of aerosols. 28, 30, 31 Such variability in EC aerosol composition highlights some of the challenges in evaluating health effects of ECs. Additionally, although the concentrations of these chemicals are often reported to be less than those found in CCs and less than occupational safety standards, 29, 35 this is not a consistent finding across all studies, 27, 30, 34 raising concern for the potential of untoward toxicities and health effects. Unfortunately, the plethora of EC brands and designs and unique flavorings available, 36 along with the ability to customize the power, resistance, and/or temperature of newer-generation ECs, results in immense difficulty in not only developing a comprehensive list of chemical constituents in EC aerosols but also developing well-designed, populationbased studies of the long-term health effects of ENDS use.
BIOLOGICAL EFFECTS
As a first step to assessing the safety of EC use, several studies have examined the biological effects of EC constituents through in vitro and animal models. However, given the hurdle presented by EC design variability and possible EL permutations, the generalizability of these studies is limited. In addition, it is well accepted that murine studies present less than ideal models for extrapolation to human subjects. Nonetheless, we present here some of the most recent data available on the effects of ECs on cytotoxicity, inflammation, barrier dysfunction, and microbial defense.
Cytotoxicity
A number of studies have evaluated the cytotoxic potential of EC liquids and aerosols either in isolation or compared with CCs. In a recent study, Behar et al 37 assessed the sensitivity of human pulmonary fibroblasts, lung epithelial cells, and human embryonic stem cells to 35 ELs and their aerosols. Twenty (57%) of the 35 ELs and 27 (77%) of 35 aerosols were found to be cytotoxic, whereas 20% of ELs and their aerosols were noncytotoxic. Embryonic stem cells were more sensitive to the cytotoxic effects of these products compared with differentiated cells, raising concern for potential effects of maternal EC use on fetal and neonatal health. Fruit-flavored, tobacco-flavored, and nicotine-free and flavor-free ELs were also cytotoxic to human pharyngeal tissue cultures, with the fruit-flavored ELs significantly increasing DNA fragmentation. 38 Similarly, decreased viability, increased oxidative stress, diminished cell proliferation, and increased DNA damage are all biological effects demonstrated in other healthy and malignant cell cultures treated with EC aerosols. [39] [40] [41] [42] In contrast, when directly comparing EC liquids and aerosols with CC smoke using identical assays, Misra et al 43 found no cytotoxic, mutagenic, or genotoxic effects of EC liquids or aerosols, a finding also reported by others. 44, 45 Of note, when reported, the degree of cytotoxicity of ECs has generally been less that that of CCs, 39, 40, [46] [47] [48] [49] supporting those who argue in favor of the harm-reduction use of ECs in chronic smokers. Inconsistent results regarding the cytotoxic effects reported among studies are likely due to variables such as cell culture models used, the brand of EC studied, the composition of ECs themselves, voltage/ wattage applied for aerosol generation, testing of the ELs itself versus the aerosol, and the method of aerosol collection. Nonetheless, available data still provide valuable information for the potential harmful effects of ECs, although less so than those of CCs, highlighting the need for additional research.
Inflammation
Similar to cytotoxic effects, inconsistent data exist on EC induction of proinflammatory responses. In vitro exposure of airway epithelial cells, pulmonary fibroblasts, and innate immune cells (ie, neutrophils and macrophages) to components of ELs and EC vapors (ie, acrolein and metals) demonstrated release of inflammatory cytokines, including IL-1b, IL-6, IL-8, IL-10, CXCL1, CXCL2, and CXCL10. [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] In an in vivo model, mice were exposed for 6 hours per day for 3 days to either control air, EC aerosol, or CC smoke. Transcriptional expression of IL-1b was significantly increased in those exposed to EC aerosol compared with control air, but overall, inflammatory cytokine expression was lower than that in mice exposed to CC smoke. 59 Similarly, exposure of mice to EC aerosol for 5 hours per day for 3 days demonstrated increased IL-6 and IL-13 cytokine levels in bronchoalveolar lavage fluid. 60 In a model of allergic inflammation, a dilute EL solution was intratracheally administered twice weekly for 10 weeks in ovalbuminsensitized mice. This resulted in increased airway eosinophilia, production of T H 2 cytokines (IL-4, IL-5, and IL-13), and ovalbumin-specific IgE production. 61 However, inflammatory responses driven by EC exposure are not a consistent finding among in vitro or in vivo murine models. Larcombe et al 62 demonstrated no increased inflammation in mice exposed for 8 weeks to EC aerosols derived from ELs with differing nicotine content and solvents. In vitro assays performed by Misra et al 43 also did not show a proinflammatory effect after exposure of human lung epithelial cells to 4 different ELs varying in flavor and nicotine concentrations and their respective vapors. In another study macrophage secretion of the inflammatory cytokines TNF-a, IL-1b, and IL-6 actually decreased when cultured on media infused with nicotine and certain flavors compared with media infused with control air. 63 Although not a consistent finding, the potential proinflammatory properties of ECs heightens the concern for promoting development or worsening of chronic inflammatory airway diseases.
Effects on barrier dysfunction, airway mucus, and clearance
In addition to cytotoxic and proinflammatory effects, EC use can also impair innate barrier defenses, although the data in favor FIG 1. EC design and constituents. ECs consist of 3 basic components: a battery source, heating element (atomizer coil), and cartridge. Heat from the atomizer coil after activation of the power source aerosolizes the EL, which is then inhaled (or ''vaped'') from the attached mouthpiece. The exact constituents detected in the vapor depends on various factors, including the flavor and solvent used, nicotine content, temperature generated, and material of the heating element. Each generation of ECs varies in size and design, with newer generations least resembling a CC. PG, Polyethylene glycol; TSNAs, tobacco-specific nitrosamines; VG, vegetable glycerin; VOCs, volatile organic compounds.
of this are nascent. Lung endothelial cell permeability, as measured by cell-substrate impedance sensing, increased after exposure to EC aerosols independent of nicotine concentration. These barrier defects enhanced oxidative stress and inflammation triggered by EC exposure. 56 Cell-substrate impedance sensing has also identified impaired lung epithelial barrier defenses secondary to exposure with various flavors, including diacetyl, coumarin, acetoin, maltol, and cinnamaldehyde, which are commonly added to ELs. 51 Similarly, exposure of mouse tracheal epithelial cells to 2,5-dimethylpyrazine (present in vanilla and chocolate flavorings) resulted in transient losses in transepithelial resistance and ion conductance. 64 The airway mucus layer also provides an important component of innate defense. Increased mucus production and altered mucus clearance are hallmarks of airway inflammation in patients with chronic conditions, including COPD and asthma. In vitro studies of normal human bronchial epithelial (NHBE) cells have been used to examine EC effects on airway mucus. NHBE cells repeatedly exposed to EC vapor over 8 weeks had a reduction in numbers of mucus-producing cells. 65 Additionally, EC vapor appears to have potential to impair mucociliary clearance through impairment of ciliary beat frequency in NHBE cells. 66 Murine studies have provided more insight on in vivo EC effects on airway mucus. Mice exposed to daily EC aerosol for 4 months had alterations in the mucus layer present in healthy airways, notably with increased production of the mucin glycoprotein 5AC (MUC5AC). 66 Increased MUC5AC levels have important implications in the pathophysiology of asthma and COPD, 67 contributing to increased airway obstruction and nonspecific airway hyperreactivity. 68 These murine studies were later confirmed in human subjects, with a recent publication noting increased levels of MUC5AC in induced sputum from both EC and CC smokers compared with nonsmokers. 69 Collectively, these data, although limited, provide evidence for impairment of important innate barrier defenses after EC exposure.
Impaired microbial defense
The previously discussed biological effects of ECs likely contribute to impaired microbe defense; other mechanisms of defective microbial defenses can also be involved, including impairment of Toll-like receptor function and phagocytosis by innate immune cells. In vitro exposure of a human macrophage cell line to ELs showed reduced surface expression of pattern recognition receptors, such as Toll-like receptors and scavenger receptors, with a subsequent decrease in macrophage phagocytosis. 63 Alveolar macrophage cultures from EC-exposed mice exhibited significant decreases in internalized Streptococcus pneumoniae with concurrent significant increases in extracellular S pneumoniae, indicating that EC exposure impaired bacterial phagocytosis. 70 Similarly, survival of methicillin-resistant Staphylococcus aureus when cultured with murine alveolar macrophages exposed to E-vapor was greater than 350% compared with being cultured with control macrophages exposed to air alone, 71 although it was unclear from these studies whether the defect existed with phagocytic capacity versus intracellular bacterial killing. Additionally, methicillin-resistant Staphylococcus aureus colonies exposed to E-vapor demonstrated enhanced virulence when inoculated into mice. 71 The adverse effects related to EC exposure also appear to affect susceptibility to viral infection. Among EC-exposed mice, experimental infection with influenza A resulted in higher viral titers and virus-related mortality. 70 Providing further evidence of immunosuppressive effects of ECs, RNA analysis of nasal scrape biopsies of EC users revealed suppression of significantly more genes involved in innate immunity compared with CC smokers. 72 Taken together, these data highlight the impairment of antibacterial and antiviral defenses that can occur with EC use and emphasizes the need for additional research to determine whether the findings in these in vitro and in vivo murine models translate to human subjects.
EFFICACY OF ECs IN SMOKING CESSATION
Trends from US population surveys over the last 10 years note an association between an increase in EC use and a concomitant increase in overall smoking cessation rates, 8 suggesting the potential role of ECs as smoking cessation tools. Although the bulk of human studies focusing on the efficacy of ECs as smoking cessation tools use observational designs, a few randomized controlled trials have been conducted. In the largest trial conducted to date, 73 657 smokers interested in quitting were randomized to receive either 16-mg nicotine ECs, 21-mg nicotine patches, or placebo ECs and were followed for 6 months. Although tobacco cessation for the entire study population was less than predicted, resulting in insufficient power to draw conclusions, abstinence was greatest in those who received nicotine ECs (7.3% vs 5.3% for nicotine patches vs 4.1% with placebo ECs). In a more recent, smaller, randomized controlled trial of 99 young adult smokers not willing to quit in New York City, a significantly greater reduction in CC use occurred in those randomized to receive a nicotine ECs versus those receiving a nicotine-free EC over a 3-week time period, 74 a finding similar to that demonstrated in 48 other smokers randomized to either receive or not receive an EC during a 2 month trial (34% vs 0% achieved tobacco cessation, respectively). 75 Alternatively, Caponnetto et al 76 demonstrated no difference in smoking reduction or quit rates among 183 smokers randomized into 3 arms to receive ECs containing either 2.4%, 1.2%, or 0% nicotine and followed for 52 weeks.
The conclusions of meta-analyses examining the effectiveness of ECs in smoking cessation might tip the scale ever so slightly in favor of their use, with the caveat that available data are of low certainty and severely limited in terms of long-term efficacy, [77] [78] [79] as demonstrated by the heterogeneity of the findings of the aforementioned randomized clinical trials. However, it should be noted that although complete cessation of CC use has clear health benefits, the benefits of reduced smoking in the setting of dual use with ECs are uncertain, as are the clinical effects of long-term EC use.
EFFECTS OF EC USE ON CLINICAL BIOMARKERS AND SYMPTOMS
A paucity of data exists on the short-term and long-term health effects of EC use in human subjects since their inception a decade ago. It is important to recognize that not all subjects will demonstrate similar measurable outcomes after initiation of EC use. Thus it is imperative to study these health effects in population subsets, such as those naive to CCs, chronic smokers who either switch to vaping or become dual users, and vulnerable subjects, including youth and those with underlying airway inflammatory disease. To this effect, we have subdivided the following discussion on the clinical effects of EC use with respect to these subgroups.
Nonsmokers
Available information on health effects in those naive to CCs is limited because most human studies have focused on comparing ECs with CCs. Ferrari et al 80 assessed the effect of smoking a CC and nicotine-free EC for 5 minutes each in both nonsmokers and smokers who were naive to ECs by using pulmonary function tests and measuring fraction of exhaled nitric oxide (FENO) and fraction of exhaled carbon monoxide. This short exposure to a nicotine-free EC revealed no significant changes in outcomes measured in this small sample size of nonsmokers (n 5 10), whereas slight decreases in lung function were noted in smokers (n 5 10). Passive exposure to cigarette smoke and EC aerosol in 2 separate sessions in 15 nonsmokers did not produce any changes in pulmonary function tests but did generate similar increases in serum cotinine levels, a biomarker and metabolite of nicotine, 81 indicating comparable nicotine absorption when exposed second-hand to either EC vapor or cigarette smoke, a finding also reported by others. 82 
Chronic CC smokers
Various measures of health-related outcomes, including biomarker assessments and changes in symptoms and lung function, have been assessed in chronic CC smokers who switch to using ECs either partially or completely. A 1-year randomized trial found that smokers who completely switched from CCs to ECs had improvements in FENO and fraction of exhaled carbon monoxide values, which also correlated with improvements in self-reported symptoms. 83 No such beneficial effects were seen in those who only partially substituted CCs with ECs. Similar improvements in biomarkers were also reported in 105 study participants who either partially or completely replaced CCs with ECs for only 5 days. 84 In contrast, decreased FENO values and increased peripheral airway resistance resulted from only 5 minutes of vaping in 30 smokers. 85 Although the authors note that small changes might not be clinically relevant, longer durations of exposure can yield more deleterious effects. However, abstaining from cigarette smoking over the course of 1 year through substitution with ECs improved forced expiratory flow at 25% to 75% of forced vital capacity, with a reduction in dyspnea and cough noted in quitters and reducers of CC use. 86 
Vulnerable populations
In those with underlying inflammatory airway disease, such as asthma and COPD, tobacco smoke has long been known to be an exacerbating factor, with studies now beginning to examine whether ECs will play a similar role in these patients. A recent study of smokers with mild intermittent asthma found increased airway resistance and reduced FENO values after a single vaping session that required twice as long to return to baseline measures compared with ''healthy'' smokers. 87 In contrast, a retrospective study evaluating complete or partial transition of CCs to ECs reported improvements in lung function, airway hyperresponsiveness, and patient-reported asthma control at 12 months in 18 smokers with mild-to-moderate asthma. 88 These improved outcomes persisted in both sole EC users and dual users after prospective follow-up for an additional 12 months. 89 Short-term or long-term health effects of EC use among asthmatic patients naive to CCs remain unknown.
Studies regarding EC use among patients with COPD yield inconsistent results. Two observational cohorts in adults at risk for or with COPD suggested worse pulmonary-related outcomes in those using ECs (either alone or in combination with CCs). 90 In contrast, a retrospective chart review noted significantly reduced COPD symptoms and exacerbations in EC users and dual users compared with those using CCs alone. 91 These limited and varying data in patients most susceptible to the potential harmful effects of ECs or, alternatively, the most likely to benefit from them stresses the need for well-designed clinical trials assessing long-term health effects in these subgroups.
In addition to those with underlying airway disease, youth represent another high-risk patient population with long-term adverse health effects from EC use. Recent studies have reported increased risk of chronic respiratory symptoms among youth who use ECs. High school juniors and seniors from Southern California who use ECs had twice the risk of reporting respiratory symptoms (chronic cough, phlegm, and/or bronchitis) compared with their nonvaping peers, even when adjusting for dual use with CCs or exposure to second-hand smoke. Additionally, risk of chronic bronchitis symptoms increased with frequency of vaping. 92 However, what is unclear is whether these symptoms are secondary to chronic airway inflammation and/or to increased susceptibility to infection. Other cross-sectional studies of adolescents support that EC use is associated with increased prevalence of asthma symptoms and chronic bronchitis. 93, 94 It will be imperative to design larger-scale longitudinal studies in those naive to CCs, with harmonized objective and patient-reported outcome measures to determine the risks of EC products on preventable infection and chronic respiratory disease in highly susceptible populations.
CONCLUSIONS AND FUTURE DIRECTIONS
Both the incidence and prevalence of ENDS use are increasing rapidly in the United States and throughout the world, being partially fueled by the general notion that ECs are harmless, particularly in comparison with CCs. Research efforts studying these assumptions have only begun to emerge in recent years. Notably, although this review focused on the potential respiratory toxicities of ECs, the addictive properties and neurocognitive effects of nicotine itself, 95 used by the overwhelming majority of EC users, as well as the effects of second-hand smoke exposure caused by ECs should certainly be considered. Likewise, physical injuries from EC explosions 96 and accidental exposure to nicotine-containing ELs, particularly in children, 97 are increasingly being reported and should enter the discussion when counseling on EC use.
In regard to pulmonary effects, airway inflammation, respiratory tract infections, increased mucus secretion, epithelial barrier defects, and oxidative stress are all features well described in the pathogenesis of asthma and COPD, as well as in acute exacerbations of these illnesses. 67, [98] [99] [100] [101] [102] [103] [104] Triggering of these same biological effects by EC use, as seen in some in vitro and in vivo models, suggests the possibility that recurrent exposure to EC has the potential to induce similar airway inflammatory disease processes. However, this has yet to be elucidated in human models but is a vital area of needed research.
Although ECs are touted frequently as less harmful than CCs, clinical data regarding the safety of EC use are still scant. Classifying a subject's smoking status is imperative when considering specific recommendations for EC use because the same recommendation might not apply to chronic smokers and those naive to CCs, such as adolescents, or those with underlying airway disease.
We have summarized the clinical data presented in this review with respect to chronic smokers and subjects naive to CCs in Figs  2 and 3 , respectively. Emerging data on clinical respiratory effects currently tip the scale slightly in favor of use of ECs by chronic smokers (compared with CC use, Fig 2) . However, the potential benefits of replacing CCs with ECs has only been demonstrated in the short term because data for long-term respiratory effects and smoking cessation efficacy with EC use are lacking, highlighting the danger in prematurely advocating prolonged EC use in smokers. In contrast, the increased risk of adopting CCs among adolescent EC users and the available short-term evidence of EC-triggered clinical respiratory effects in those naive to CC tip the scale against ECs for these subjects (Fig 3) . Further research efforts should be devoted to studying the long-term respiratory effects in these specific population subgroups, particularly in youth with underlying respiratory conditions, such as asthma, who might be more prone to EC use compared with their nonasthmatic peers. 105 This information will allow for individualized recommendations of EC use and guidance for appropriate federal regulatory measures.
Additionally, to date, most studies are observational or retrospective studies, which inherently are fraught with biases and, as mentioned before, only assess the short-term effects of ECs in small sample sizes. Moreover, some research efforts are funded by EC manufactures or antismoking foundations, necessitating caution in interpretation of data. Little consistency in methodologies and outcome measurements between studies limits the accumulation of reproducible data from which to draw meaningful conclusions. The inconsistency in available data could possibly suggest that various features of ECs might work in concert to either promote or prevent harmful effects (eg, particular flavors, nicotine content, base solvent, power used, and frequency of exposure). As previously discussed, the vast array of device designs and EL combinations available to consumers presents an insurmountable hurdle for the research community in obtaining reproducible results that can be compiled and compared.
For these reasons, both the regulation and standardization of ENDSs are imperative for the protection of vulnerable populations against future tobacco use, for protection against the development of chronic preventable disease should harm be incurred by use of these products, and for development of welldesigned and unbiased generalizable longitudinal trials. Although a number of regulatory efforts have already taken place, 106 additional research efforts are urgently needed to further guide legislative processes of this booming industry, as highlighted by the recent recommendations of the ENDS Committee under the National Academies of Sciences, Engineering, and Medicine. 107 Although the last decade of research has made important contributions to our current understanding of ECs, the uncertainty that remains regarding the safety and efficacy of ECs (Table I) needs to be addressed to arm the medical and lay community with the knowledge necessary to promote long-term health and well-being. 
